User: Guest  Login
Less Searchfields
Simple search
Title:

Supplementation with Bifidobacterium longum subspecies infantis EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol.

Document type:
Journal Article
Author(s):
Ziegler, Anette-Gabriele; Arnolds, Stefanie; Kölln, Annika; Achenbach, Peter; Berner, Reinhard; Bonifacio, Ezio; Casteels, Kristina; Elding Larsson, Helena; Gündert, Melanie; Hasford, Joerg; Kordonouri, Olga; Lundgren, Markus; Oltarzewski, Mariusz; Pekalski, Marcin L; Pfirrmann, Markus; Snape, Matthew D; Szypowska, Agnieszka; Todd, John A
Abstract:
INTRODUCTION: The Global Platform for the Prevention of Autoimmune Diabetes-SINT1A Study is designed as a randomised, placebo-controlled, double-blind, multicentre, multinational, primary prevention study aiming to assess whether daily administration of Bifidobacterium infantis from age 7 days to 6 weeks until age 12 months to children with elevated genetic risk for type 1 diabetes reduces the cumulative incidence of beta-cell autoantibodies in childhood. METHODS AND ANALYSIS: Infants aged 7 day...     »
Journal title abbreviation:
BMJ Open
Year:
2021
Journal volume:
11
Journal issue:
11
Fulltext / DOI:
doi:10.1136/bmjopen-2021-052449
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/34753762
Print-ISSN:
2044-6055
TUM Institution:
Klinik und Poliklinik für Kinder- und Jugendmedizin
 BibTeX